Lead, Medical Education & Funding

GSK•Philadelphia, PA

About The Position

At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Lead the enterprise management and execution of all HCRO funding (including IME) across USMA and external partners, translating therapeutic-area strategies into high‑integrity grants, sponsorships, and other funding mechanisms while driving funding excellence and cross-organizational alignment. Ensure executional excellence and compliance with GSK policy and external standards (OIG, FDA, PhRMA, ACCME) by overseeing Smartsheet/GMS/third‑party platforms, payment services, data interfaces, external web/email channels, and transparent statutory reporting. Serve as a medical grant steward and matrix business partner—advising therapeutic areas on innovative, outcomes‑focused proposals; leading a team of medical reviewers/approvers and serve on enterprise grant committees; driving process simplification, technical consultation, and a high‑performing team to optimize resource allocation and delivery.

Requirements

Bachelor’s Degree in Life Sciences, Health Sciences, Communications, Business, or related field required.
Eight or more years of experience in the pharmaceutical/biotechnology industry .
Two or more years of experience in leadership/complex program management roles.
Three or more years of relevant pharmaceutical/biotechnology industry experience with HCRO funding experience.

Nice To Haves

MS or PhD. Degree in related field.
Four or more years of experience in leadership/complex program management roles.
Five or more years of HCRO funding experience.

Responsibilities

Enterprise management of all HCRO funding between USMA and key external organizations – driving execution excellence on behalf of TA strategies.
Accountable for HCRO funding execution, collaborating and aligning with the broader organization on significant gaps and systematic approaches to overcome barriers to improvement.
Partner with TAs to identify/recommend and then subsequently execute high-integrity and quality medical education proposals & sponsorships, incorporating innovative approaches to address healthcare gaps and quality/performance improvement opportunities.
Serve as a grant approver by proxy on behalf of TA and medical business leader on enterprise-wide business unit grant committees.
Ensure that all HCRO funding, including IME and non-IME grants meet GSK policies/guidelines and comply with standards from OIG, FDA, PhRMA Code, ACCME, and other accrediting bodies.
Oversee successful execution, continuous management, and support of the enterprise-wide systems for managing overall HCRO funding, including Smartsheet, Grant Management System, and any associated third-party outsourcing.
Manage HCRO payment services including procurement, GMS payment services, work with USMA platforms to resolve technical issues, and oversee data interfaces integral to HCRO funding and reporting.
Manage all HCRO related website content (GSK Grants) and email accounts
Lead process improvement and simplification efforts regarding complex HCRO Funding-related initiatives with cross-functional teams within USMA and the GSK enterprise.
Consult on technical and complex issues arising from funding-related business processes across USMA and the enterprise.
Ensure complete and accurate grant data reporting to comply with GSK voluntary transparency and statutory requirements.
Lead, coach and develop a high performing team; set clear goals and optimize resource allocation across therapeutic areas and funding types.